• Antinori, A., Cingolani, A., Alba, L., Ammassari, A., Serraino, D., Ciancio, B.C., Palmieri, F., De Luca, A., Larocca, L.M., Ruco, L., Ippolito, G. & Cauda, R. (2001) Better response to chemotherapy and prolonged survival in AIDS-related response to highly active antiretroviral therapy. AIDS, 15, 14831491.
  • Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R. & Costagliola, D. (2006) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 24, 41234128.
  • Bower, M., Gazzard, B., Mandalia, S., Newsom-Davis, T., Thirlwell, C., Dhillon, T., Young, A.M., Powles, T., Gaya, A., Nelson, M. & Stebbing, J. (2005) A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Annals of Internal Medicine, 143, 265273.
  • Carbone, P.P., Kaplan, H.S., Musshoff Ksmithers, D.W. & Tubiana, M. (1971) Report of the Committee on Non-Hodgkin’s Disease Classification. Cancer Research, 31, 18601861.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology, 17, 12441253.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Cox, D.R. (1972) Regresion models and life tables. Journal of the Royal Statistical Society, 3, 187200.
  • Diamond, C., Taylor, T.H., Im, T. & Anton-Culver, H. (2006) Presentaiton and outcomes of systemic non-Hodgkin’s lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leukaemia & Lymphoma, 47, 18821889.
  • Engels, E.A., Pffeiffer, R.M., Goedert, J.J., Virgo, P., McNeel, T.S., Scoppa, S.M. & Biggar, R.J. (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS, 20, 16451654.
  • Harris, N., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 38353849.
  • International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine, 329, 987994.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J.A., Cesarman, E., Chadburn, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin’s lymphoma.AIDS Malignancies Consortium Trial 010. Blood, 106, 15381543.
  • Lewden, C., Salmon, D., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T. & Chene, G. (2005) Causes of death among human immunodeficiency virus (HIV) infected adults in the era of potent antiretroviral therapy. Emerging roles of hepatitis and cancer, persistent role of AIDS. International Journal of Epidemiology, 34, 121130.
  • Lim, S.T., Karim, R., Tulpule, A., Nathwani, B.N. & Levine, A.M. (2005) Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Journal of Clinical Oncology, 23, 84778482.
  • Little, R.F., Pittaluga, S., Grant, N., Steinberg, S.M., Kavlick, M.F., Mitsuya, H., Franchini, G., Gutierrez, M., Raffeld, M., Jaffe, E.S., Shearer, G., Yarchoan, R. & Wilson, W.H. (2003) Highly effective treatment of acquired inmmunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood, 101, 46534659.
  • Miralles, P., Berenguer, J., Ribera, J.M., Rubio, R., Mahillo, B., Tellez, M.J., Lacruz, J., Valencia, E., Santos, J., Rodríguez-Arrondo, F. & Pintado, V. (2007) Prognosis of AIDS-related systemic non-Hodgkin’s lymphoma treated with chemotherapy and HAART depends exclusively on tumor-related factors. Journal of AIDS, 44, 167173.
  • Navarro, W.H. & Kaplan, L.D. (2006) AIDS-related lymphoproliferative disease. Blood, 107, 1320.
  • Navarro, J.T., Ribera, J.M., Oriol, A., Romeu, J., Sirera, G., Mate, J.L., Batlle, M., Xicoy, B., Grau, J., Milla, F. & Feliu, E. (2002) Favorable impact of virologic response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leukaemia & Lymphoma, 43, 18371842.
  • Navarro, J.T., Lloveras, N., Ribera, J.M., Oriol, A., Mate, J.L. & Feliu, E. (2005) The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine, and prednisone (CHOP), and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving CHOP. Haematologica, 90, 703705.
  • Oriol, A., Ribera, J.M., Brunet, S., Del Potro, E., Abella, E. & Esteve, J. (2005) Influence of highly active antiretroviral therapy in the outcome of AIDS-related Burkitt’s lymphoma or leukemia. Results of the PETHEMA-LAL3/97. Haematologica, 90, 990992.
  • Peto, R. & Pike, M.C. (1973) Conservatism of the approximation Σ(O-E)2/E in the log-rank test for survival data or tumor incidence data. Biometrics, 29, 579584.
  • Pfreundschuh, M.G., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffer, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379391.
  • Sparano, J.A., Lee, S., Chen, M.G., Nazeer, T., Einzig, A., Ambinder, R.F., Henry, D.H., Manalo, J., Li, T. & Von Roenn, J.H. (2004) Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma. An Eastern Cooperative Oncology Group trial (E1494). Journal of Clinical Oncology, 22, 14911500.
  • Spina, M., Carbone, A., Vaccher, E., Gloghini, A., Talamini, R., Cinelli, R., Martellotta, F. & Tirelli, U. (2004) Outcome of patients with non-Hodgkin lymphoma with or without human immunodeficiency virus infection. Clinical Infectious Diseases, 38, 142144.
  • Spina, M., Jaeger, U., Sparano, J.A., Talamini, R., Simonelli, C., Michieli, M., Rossi, G., Nigra, E., Berretta, M., Cattaneo, C., Rieger, A.C., Vaccher, E. & Tirelli, U. (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood, 105, 18911897.
  • Spina, M., Simonelli, C. & Tirelli, U. (2007) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 25, e7.